Skin Deep: Punch Biopsies Detect Synucleinopathies
In a small sample set, phosphorylated α-synuclein was detected in the dermis of four such disorders.
588 RESULTS
Sort By:
In a small sample set, phosphorylated α-synuclein was detected in the dermis of four such disorders.
Researchers at AD/PD showcased progress in modeling these conditions, detecting CAA, and potentially mitigating microhemorrhages.
A new immunoassay detects N-terminal fragments of tau. They predict tangle accumulation, cortical atrophy, and cognitive decline.
Using different methods and studying different populations, two studies report similar trajectories of fluid and imaging biomarkers over a 20-year span of AD.
In more than 52,000 cognitively healthy people, elevated plasma GFAP or NfL more than doubled the risk the person would develop dementia over the next 14 years.
A large, unbiased study found 125 proteins in the CSF that tick up or down in early familial AD. A set of nine identified FAD mutation carriers better than did Aβ and tau.
In mice, these Aβ fibrils avoid riling microglia and astrocytes. They also evade both PiB and lecanemab.
With newly available fluid biomarkers that detect α-synuclein pathology in the brain, researchers articulate ways to classify the disease based on its biology.
Among 1,092 people with PCA, symptoms started around age 60, and 94 percent had amyloid plaques or neurofibrillary tangles.
Scientists around the globe are studying how best to deploy Alzheimer's plasma tests in the real world. Their focus: primary care.
ALZpath’s assay detected an annual rise in plasma phospho-tau217 in amyloid-positive people, with the steepest increase in those who also have tangles.
The biomarker may signal tau’s early days of entanglement, and serve as a useful disease staging indicator, according to a new immunoassay.
Growth-associated protein 43 in the CSF identified people who accumulated tangles fastest. These spread through connected brain regions.
Last summer saw a first: the traditional approval of a disease-modifying Alzheimer's therapy. Solid progress on biomarkers, and a flourishing of basic research, made for a good year.
In people on Entresto, Aβ42 and Aβ40 shot up over six months. The Aβ42/40 ratio fell by a third.